Primary membranous nephropathy with nephrotic syndrome
ICD-10 N04.21 is a billable code used to indicate a diagnosis of primary membranous nephropathy with nephrotic syndrome.
Primary membranous nephropathy (PMN) is a kidney disorder characterized by the presence of immune complex deposits along the glomerular basement membrane, leading to nephron damage. This condition is often associated with nephrotic syndrome, which is defined by a triad of symptoms: significant proteinuria (greater than 3.5 grams per day), hypoalbuminemia, and edema. Patients may present with hematuria, hypertension, and renal insufficiency. Diagnosis typically involves renal biopsy, which reveals thickening of the glomerular capillary walls and subepithelial immune complex deposits. Management of PMN with nephrotic syndrome may include corticosteroids, immunosuppressive agents, and supportive care to control symptoms and prevent complications such as thromboembolism and infections. Regular monitoring of renal function and proteinuria is essential to assess treatment efficacy and disease progression.
Detailed clinical notes on symptoms, lab results, and treatment plans are essential. Documentation of renal biopsy findings and follow-up assessments is critical.
Patients presenting with edema, proteinuria, and renal impairment; management of nephrotic syndrome complications.
Ensure accurate differentiation between primary and secondary causes of nephropathy to avoid coding errors.
Pathology reports must clearly describe biopsy findings, including the presence of immune complex deposits.
Evaluation of renal biopsies for suspected membranous nephropathy.
Pathology documentation should correlate with nephrology notes for comprehensive coding.
Used when a renal biopsy is performed to confirm diagnosis.
Pathology report and clinical notes supporting the need for biopsy.
Nephrology and pathology must coordinate documentation for accurate coding.
The exact cause of primary membranous nephropathy is often unknown, but it is believed to be related to autoimmune processes where antibodies target podocyte antigens.
